<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0701256530
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OXETINE 20MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUOXETINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        37.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>OXETINE Film-Coated Tablets contain the active<br />substance Fluoxetine which is one of a group of<br />medicines called selective serotonin re-uptake<br />inhibitors (SSRI) antidepressants. This medicine is<br />used to treat the following conditions:<br />Adults:<br />□ Major depressive episodes.<br />□ Obsessive-compulsive disorder.<br />□ Bulimia nervosa: OXETINE is used alongside<br />psychotherapy for the reduction of binge-eating and<br />purging.<br />Children and adolescents aged 8 years and<br />above:<br />Moderate to severe major depressive disorder, if the<br />depression does not respond to psychological<br />therapy after 4-6 sessions. OXETINE should be<br />offered to a child or young person with moderate to<br />severe major depressive disorder only in combination<br />with psychological therapy.<br />How OXETINE works<br />Everyone has a substance called serotonin in their<br />brain. People who are depressed or have obsessive<br />compulsive disorder or bulimia nervosa have lower<br />levels of serotonin than others. It is not fully<br />understood how OXETINE and other SSRIs work but<br />they may help by increasing the level of serotonin in<br />the brain. Treating these conditions is important to<br />help you get better.<br />If it&rsquo;s not treated, your condition may not go away<br />and may become more serious and more difficult to<br />treat. You may need to be treated for a few weeks or<br />months to ensure that you are free from symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take OXETINE if you are:<br />□ Allergic to Fluoxetine or any of the other<br />ingredients of this medicine (listed in section 6). If<br />you develop a rash or other allergic reactions (like<br />itching, swollen lips or face or shortness of breath),<br />stop taking the tablets straight away and contact your<br />doctor immediately.<br />□ Taking other medicines known as irreversible,<br />non-selective monoamine oxidase inhibitors<br />(MAOIs), since serious or even fatal reactions can<br />occur (e.g. iproniazid used to treat depression).<br />Treatment with OXETINE should only be started at<br />least 2 weeks after discontinuation of an irreversible,<br />non-selective MAOI.<br />Do not take any irreversible, non-selective MAOIs for<br />at least 5 weeks after you stop taking OXETINE. If<br />OXETINE has been prescribed for a long period<br />and/or at a high dose, a longer interval needs to be<br />considered by your doctor.<br />- Taking metoprolol (to treat heart failure) since there<br />is an increased risk of your heart beat becoming too<br />slow.<br />Take special care with OXETINE:<br />Talk to your doctor or pharmacist before taking<br />OXETINE if any of the following applies to you:<br />□ Heart problems; □ Appearance of fever, muscle<br />stiffness or tremor, changes in your mental state like<br />confusion, irritability and extreme agitation; you may<br />suffer from the so-called &ldquo;serotonin syndrome&rdquo; or<br />&ldquo;neuroleptic malignant syndrome&rdquo;. Although this<br />syndrome occurs rarely it may result in potentially life<br />threatening conditions; contact your doctor<br />immediately, since OXETINE might need to be<br />discontinued.<br />□ Mania now or in the past; if you have a manic<br />episode, contact your doctor immediately because<br />OXETINE might need to be discontinued.<br />□ History of bleeding disorders or appearance of<br />bruises or unusual bleeding.<br />□ Ongoing treatment with medicines that thin the<br />blood (see &lsquo;Other medicines and OXETINE&rsquo;).<br />□ Epilepsy or fits. If you have a fit (seizures) or<br />experience an increase in seizure frequency, contact<br />your doctor immediately;<br />OXETINE might need to be discontinued.<br />□ Ongoing ECT (electro-convulsive therapy)<br />□ Ongoing treatment with tamoxifen (used to treat<br />breast cancer) (see &lsquo;Other medicines and<br />OXETINE&rsquo;).<br />□ Starting to feel restless and cannot sit or stand still<br />(akathisia). Increasing your dose of OXETINE may<br />make this worse.<br />□ Diabetes (your doctor may need to adjust your<br />dose of insulin or other antidiabetic treatment).<br />□ Liver problems (your doctor may need to adjust<br />your dosage).<br />□ Low resting heart-rate and/or if you know that you<br />may have salt depletion as a result of prolonged<br />severe diarrhoea and vomiting (being sick) or usage<br />of diuretics (water tablets) □ Ongoing treatment with<br />diuretics (water tablets), especially if you are elderly<br />□ Glaucoma (increased pressure in the eye).<br />Thoughts of suicide and worsening of your<br />depression or anxiety disorder:<br />If you are depressed and/or have anxiety disorders<br />you can sometimes have thoughts of harming or<br />killing yourself. These may be increased when first<br />starting antidepressants, since these medicines all<br />take time to work, usually about two weeks but<br />sometimes longer.<br />You may be more likely to think like this:<br />□ If you have previously had thoughts about killing or<br />harming yourself.<br />□ If you are a young adult. Information from clinical<br />trials has shown an increased risk of suicidal<br />behavior in adults aged less than 25 years with<br />psychiatric conditions who were treated with an<br />antidepressant.<br />If you have thoughts of harming or killing yourself at<br />any time, contact your doctor or go to a hospital<br />straight away.<br />You may find it helpful to tell a relative or close friend<br />that you are depressed or have an anxiety disorder,<br />and ask them to read this leaflet. You might ask them<br />to tell you if they think your depression or anxiety is<br />getting worse, or if they are worried about changes in<br />your behaviour.<br />Children and adolescents aged 8 to 18 years:<br />Patients under 18 have an increased risk of<br />side-effects such as suicide attempt, suicidal<br />thoughts and hostility (predominantly aggression,<br />oppositional behaviour and anger) when they take<br />this class of medicines. OXETINE should only be<br />used in children and adolescents aged 8 to 18 years<br />for the treatment of moderate to severe major<br />depressive episodes (in combination with psychological<br />therapy) and it should not be used to treat other<br />conditions.<br />Additionally, only limited information concerning the<br />long-term safety of OXETINE on growth, puberty,<br />mental, emotional and behavioural development in<br />this age group is available. Despite this, and if you<br />are a patient under 18, your doctor may prescribe<br />OXETINE for moderate to severe major depressive<br />episodes, in combination with psychological therapy,<br />because he/she decides that this is in your best<br />interests. If your doctor has prescribed OXETINE for<br />a patient under 18 and you want to discuss this,<br />please go back to your doctor. You should inform<br />your doctor if any of the symptoms listed above<br />develop or worsen when patients under 18 are taking<br />OXETINE.<br />OXETINE should not be used in the treatment of<br />children under the age of 8 years.<br />Sexual dysfunction<br />Medicines like OXETINE (so called SSRIs) may<br />cause symptoms of sexual dysfunction (see section<br />4). In some cases, these symptoms have continued<br />after stopping treatment.<br />- SSRIs/ SNRIs may increase the risk of postpartum<br />haemorrhage.<br />Taking other medicines with OXETINE:<br />Tell your doctor or pharmacist if you are taking, have<br />recently taken or might take any other medicines.<br />Do not take OXETINE with:<br />□ Certain irreversible, non-selective monoamine<br />oxidase inhibitors (MAOIs) some used to treat<br />depression. Irreversible, non-selective MAOIs must<br />not be used with OXETINE as serious or even fatal<br />reactions (serotonin syndrome) can occur (see<br />section &ldquo;Do not take OXETINE&rdquo;). Treatment with<br />OXETINE should only be started at least 2 weeks<br />after discontinuation of an irreversible, non-selective<br />MAOI (for instance tranylcypromine). Do not take any<br />irreversible, non-selective MAOIs for at least 5 weeks<br />after you stop taking OXETINE. If OXETINE has<br />been prescribed for a long period and/or at a high<br />dose, a longer interval than 5 weeks may need to be<br />considered by your doctor.<br />□ metoprolol when used for heart failure; there is an<br />increased risk of your heart beat becoming too slow.<br />OXETINE may affect the way the following<br />medicines work (interaction):<br />□ Tamoxifen (used to treat breast cancer), because<br />OXETINE may change the blood levels of this drug,<br />resulting in the possibility of a reduction in the effect<br />of tamoxifen, your doctor may need to consider<br />prescribing a different antidepressant treatment.<br />□ Monoamine oxidase inhibitors A (MAOI-A)<br />including moclobemide, linezolid (an antibiotic) and<br />methylthioninium chloride (also called methylene<br />blue, used for the treatment of medicinal or chemical<br />product induced methemoglobinemia): due to the<br />risk of serious or even fatal reactions (called<br />serotonin syndrome). Treatment with fluoxetine can<br />be started the day after stopping treatment with<br />reversible MAOIs but the doctor may wish to monitor<br />you carefully and use a lower dose of the MAOI-A<br />drug.<br />□ Mequitazine (for allergies), because taking this<br />drug with OXETINE may increase the risk of<br />changes in the electrical activity of the heart.<br />□ Phenytoin (for epilepsy), because OXETINE may<br />influence the blood levels of this drug, your doctor<br />may need to introduce phenytoin more carefully and<br />carry out check-ups when given with OXETINE.<br />□ Lithium, selegiline, St. John&rsquo;s Wort, tramadol (a<br />painkiller), triptans (for migraine) and tryptophan,<br />there is an increased risk of mild serotonin<br />syndrome when these drugs are taken with<br />OXETINE. Your doctor will carry out more frequent<br />check-ups.<br />□ Medicines that may affect the heart&rsquo;s rhythm, e.g.<br />Class IA and III antiarrhythmics, antipsychotics (e.g.<br />phenothiazine derivatives, pimozide, haloperidol),<br />tricyclic antidepressants, certain antimicrobial<br />agents (e.g. sparfloxacin, moxifloxacin, erythromycin<br />IV, pentamidine), anti-malaria treatment particularly<br />halofantrine or certain antihistamines (astemizole,<br />mizolastine), because taking one or more of these<br />drugs with OXETINE may increase the risk of<br />changes in the electrical activity of the heart.<br />□ Anti-coagulants (such as warfarin), NSAID (such<br />as ibruprofen, diclofenac), aspirin and other<br />medicines which can thin the blood (including<br />clozapine, used to treat certain mental disorders).<br />OXETINE may alter the effect of these medicines on<br />the blood. If OXETINE treatment is started or<br />stopped when you are taking warfarin, your doctor<br />will need to perform certain tests, adjust your dose<br />and check on you more frequently.<br />□ Cyproheptadine (for allergies), because it may<br />reduce the effect of OXETINE.<br />□ Drugs that lower sodium levels in the blood<br />(including, drug that causes increase in urination,<br />desmopressin, carbamazepine and oxcarbazepine);<br />because these drugs may increase the risk of<br />sodium levels in the blood becoming too low when<br />taken with OXETINE.<br />□ Anti-depressants such as tricyclic<br />anti-depressants, other selective serotonin reuptake<br />inhibitors (SSRIs) or bupropion, mefloquine or<br />chloroquine (used to treat malaria), tramadol (used<br />to treat severe pain) or anti-psychotics such as<br />phenothiazines or butyrophenones, because<br />OXETINE may increase the risk of seizures when<br />taken with these medicines.<br />□ Flecainide, propafenone, nebivolol or encainide<br />(for heart problems), carbamazepine (for epilepsy),<br />atomoxetine or tricyclic antidepressants (for<br />example imipramine, desipramine and amitriptyline)<br />or risperidone (for schizophrenia); because<br />OXETINE may possibly change the blood levels of<br />these medicines, your doctor may need to lower<br />their dose when administered with OXETINE.<br />Taking OXETINE with food, drink and alcohol:<br />You can take OXETINE with or without food,<br />whatever you prefer. You should avoid alcohol while<br />you are taking this medicine.<br />Pregnancy, breastfeeding and fertility:<br />If you are pregnant or breast-feeding, think you may<br />be pregnant or are planning to have a baby, ask<br />your doctor or pharmacist for advice<br />before taking this medicine.<br />Pregnancy:<br />□ Talk to your doctor as soon as possible if you&#39;re<br />pregnant, if you might be pregnant, or if you&#39;re<br />planning to become pregnant.<br />□ In babies whose mothers took fluoxetine during<br />the first few months of pregnancy, there have been<br />some studies describing an increased risk of birth<br />defects affecting the heart. In the general<br />population, about 1 in 100 babies are born with a<br />heart defect. This increased to about 2 in 100 babies<br />in mothers who took fluoxetine.<br />□ When taken during pregnancy, particularly in the<br />last 3 months of pregnancy, medicines like<br />fluoxetine may increase the risk of a serious<br />condition in babies, called persistent pulmonary<br />hypertension of the newborn (PPHN), making the<br />baby breathe faster and appear bluish. These<br />symptoms usually begin during the first 24 hours<br />after the baby is born. If this happens to your baby<br />you should contact your midwife and/or doctor<br />immediately.<br />□ It is preferable not to use this treatment during<br />pregnancy unless the potential benefit outweighs<br />the potential risk. Thus, you and your doctor may<br />decide to gradually stop taking OXETINE while you<br />are pregnant or before being pregnant. However,<br />depending on your circumstances, your doctor may<br />suggest that it is better for you to keep taking<br />OXETINE.<br />□ Caution should be exercised when used during<br />pregnancy, especially during late pregnancy or just<br />before giving birth since the following effects have<br />been reported in new born children: irritability,<br />tremor, muscle weakness, persistent crying, and<br />difficulty in sucking or in sleeping.<br />Breastfeeding:<br />Fluoxetine is excreted in breast milk and can cause<br />side effects in babies. You should only breast-feed if<br />it is clearly necessary. If breast-feeding is continued,<br />your doctor may prescribe a lower dose of<br />Fluoxetine.<br />Fertility:<br />Fluoxetine has been shown to reduce the quality of<br />sperm in animal studies. Theoretically, this could<br />affect fertility, but impact on human fertility has not<br />been observed as yet.<br />* Observational data indicate an increased risk (less<br />than 2- fold) of postpartum hemorrhage following<br />SSRI/ SNRI exposure within the month prior to birth.<br />Driving and using machines:<br />Psychotropic drugs such as OXETINE may affect<br />your judgment or co-ordination. Do not drive or use<br />machinery until you know how OXETINE affects<br />you.<br />Important information about some of the<br />ingredients of OXETINE:<br />OXETINE tablets contain lactose (a type of sugar). If<br />you have been told by your doctor that you have an<br />intolerance to some sugars, contact your doctor<br />before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or<br />pharmacist has told you.<br />Check with your doctor or pharmacist if you are not<br />sure. Do not take more tablets than your doctor tells<br />you.<br />Swallow the tablets with a drink of water. Do not<br />chew the tablets.<br />Adults:<br />The recommended dose is:<br />□ Depression: The recommended dose is 1 Tablet<br />(20 mg) daily. Your doctor will review and adjust your<br />dosage if necessary within 3 to 4 weeks of the start<br />of treatment. If required, the dosage can be<br />gradually increased up to a maximum of 3 Tablets<br />(60 mg) daily. The dose should be increased<br />carefully to ensure that you receive the lowest<br />effective dose. You may not feel better immediately<br />when you first start taking your medicine for<br />depression. This is usual because an improvement<br />in depressive symptoms may not occur until after<br />the first few weeks. Patients with depression should<br />be treated for at least 6 months.<br />□ Bulimia nervosa: The recommended dose is 3<br />Tablets (60 mg) daily.<br />□ Obsessive-compulsive disorder: The<br />recommended dose is 1 Tablet (20 mg) daily. Your<br />doctor will review and adjust your dosage if<br />necessary after 2 weeks of treatment. If required,<br />the dosage can be gradually increased up to a<br />maximum of 3 Tablets (60 mg) daily. If no improvement<br />is noted within 10 weeks, your doctor will<br />reconsider your treatment.<br />Use in children and adolescents aged 8 to 18<br />years with depression:<br />Treatment should be started and be supervised by a<br />specialist. The starting dose is 10 mg/day. After 1 to<br />2 weeks, your doctor may increase the dose to 20<br />mg/day. The dose should be increased carefully to<br />ensure that you receive the lowest effective dose.<br />Lower weight children may need lower doses. If<br />there is a satisfactory response to treatment, your<br />doctor will review the need for continuing treatment<br />beyond 6 months. If you have not improved within 9<br />weeks, your doctor will reassess your treatment.<br />Elderly:<br />Your doctor will increase the dose with more caution<br />and the daily dose should generally not exceed 2<br />Tablets (40 mg). The maximum dose is 3 Tablets<br />(60 mg) daily.<br />Liver impairment:<br />If you have a liver problem or are using other<br />medication that might affect OXETINE, your doctor<br />may decide to prescribe a lower dose or tell you to<br />use OXETINE every other day.<br />If you take more OXETINE than you should:<br />□ If you take too many Tablets, go to your nearest<br />hospital emergency department or tell your doctor<br />straight away.<br />□ Take the pack of OXETINE with you if you can.<br />Symptoms of overdose include: nausea, vomiting,<br />seizures, heart problems (like irregular heart beat<br />and cardiac arrest), lung problems and change in<br />mental condition ranging from agitation to coma.<br />If you forget to take OXETINE:<br />□ If you miss a dose, do not worry. Take your next<br />dose the next day at the usual time. Do not take a<br />double dose to make up for a forgotten dose.<br />□ Taking your medicine at the same time each day<br />may help you to remember to take it regularly.<br />If you stop taking OXETINE:<br />□ Do not stop taking OXETINE without asking your<br />doctor first, even when you start to feel better. It is<br />important that you keep taking your medicine.<br />□ Make sure you do not run out of tablets.<br />You may notice the following effects (withdrawal<br />effects) when you stop taking OXETINE: dizziness,<br />tingling feelings like pins and needle, sleep<br />disturbances (vivid dreams, nightmares, inability to<br />sleep), feeling restless or agitated, unusual tiredness<br />or weakness, feeling anxious, nausea/vomiting<br />(feeling sick or being sick), tremor (shakiness),<br />headaches.<br />Most people find that any symptoms on stopping<br />OXETINE are mild and disappear within a few<br />weeks. If you experience symptoms when you stop<br />treatment, contact your doctor.<br />When stopping OXETINE, your doctor will help you<br />to reduce your dose slowly over one or two weeks &ndash;<br />this should help reduce the chance of withdrawal<br />effects. If you have any further questions on the use<br />of this medicine, ask your doctor or pharmacist.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>. POSSIBLE SIDE EFFECTS<br />Like all medicines, this medicine can cause side<br />effects, although not everybody gets them.<br />□ If you have thoughts of harming or killing yourself<br />at any time, contact your doctor or go to a hospital<br />straight away. (see section 2)<br />□ If you get a rash or allergic reaction such as<br />itching, swollen lips/tongue or wheezing/shortness of<br />breath, stop taking the tablets straight away and tell<br />your doctor immediately. □ If you feel restless and<br />cannot sit or stand still, you may have akathisia,<br />increasing your dose of OXETINE may make you<br />feel worse. If you feel like this, contact your doctor.<br />□ Tell your doctor immediately if your skin starts to<br />turn red or you develop a varied skin reaction or your<br />skin starts to blister or peel. This is very rare. The<br />most frequent sides effects (very common side<br />effects that may affect more than 1 user in 10) are<br />insomnia, headache, diarrhoea, feeling sick (nausea)<br />and fatigue.<br />Some patients have had:<br />□ A combination of symptoms (known as &ldquo;serotonin<br />syndrome&rdquo;) including unexplained fever with faster<br />breathing or heart rate, sweating, muscle stiffness<br />or tremor, confusion, extreme agitation or sleepiness<br />(only rarely). □ Feelings of weakness, drowsiness or<br />confusion mostly in elderly people and in (elderly)<br />people taking diuretics (water tablets). □ Prolonged<br />and painful erection □ Irritability and extreme<br />agitation.<br />□ Heart problems, such as fast or irregular heart<br />rate, fainting, collapsing or dizziness upon standing<br />which may indicate abnormal<br />functioning of the heart rate.<br />If you have any of the above side effects, you should<br />tell your doctor immediately.<br />The following side effects have also been reported in<br />patients taking OXETINE:<br />Common (may affect up to 1 in 10 people):<br />□ Not feeling hungry, weight loss □ Nervousness,<br />anxiety □ Restlessness, poor concentration<br />□ Feeling tense<br />□ Decreased sex drive or sexual problems (including<br />difficulty maintaining an erection for sexual activity)<br />□ Sleep problems, unusual dreams, tiredness or<br />sleepiness □ Dizziness □ Change in taste<br />□ Uncontrollable shaking movements □ Blurred<br />vision □ Rapid and irregular heartbeat sensations<br />□ Flushing □ Yawning □ Indigestion, vomiting □ Dry<br />mouth □ Rash, urticaria, itching □ Excessive<br />sweating □ Joint pain □ Passing urine more<br />frequently □ Unexplained vaginal bleeding<br />□ Feeling shaky or chills<br />Uncommon (may affect up to 1 in 100 people):<br />□ Feeling detached from yourself □ Strange thinking<br />□ Abnormally high mood □ sexual problems,<br />including orgasm problems, occasionally persisting<br />after treatment discontinuation □ Thoughts of<br />suicide or harming yourself □ Teeth grinding<br />□ Muscle twitching, involuntary movements or<br />problems with balance or co-ordination □ Memory<br />impairment □ Enlarged (dilated) pupils □ Ringing<br />in the ears □ Low blood pressure □ Shortness of<br />breath □ Nose bleeds □ Difficulty swallowing □ Hair<br />loss □ Increased tendency to bruising<br />□ Unexplained bruising or bleeding □ Cold sweat<br />□ Difficulty passing urine □ Feeling hot or cold<br />□ Abnormal liver test results<br />Rare (may affect up to 1 in 1,000 people):<br />□ Low levels of salt in the blood □ Reduction in<br />blood platelets, which increases risk of bleeding or<br />bruising □ Reduction in white blood cell count<br />□ Untypical wild behaviour □ Hallucinations<br />□ Agitation □ Panic attacks □ Confusion<br />□ Stuttering □ Aggression □ Fits □ Vasculitis<br />(inflammation of a blood vessel) □ Rapid<br />swelling of the tissues around the neck, face, mouth<br />and/or throat □ Pain in the tube that takes food or<br />water to your stomach □ Hepatitis □ Lung<br />problems □ Sensitivity to sunlight □ Muscle pain<br />□ Problems urinating □ Producing breast milk<br />Bone fractures - an increased risk of bone fractures<br />has been observed in patients taking this type of<br />medicines.<br />Most of these side effects are likely to disappear with<br />continued treatment.<br />In children and adolescents (8-18 years) &ndash; In<br />addition to the possible side effects listed above,<br />OXETINE may slow growth or possibly delay sexual<br />maturity. Suicide-related behaviours (suicide attempt<br />and suicidal thoughts), hostility, mania, and nose<br />bleeds were also commonly reported in children.<br />Frequency not known:<br />□ Postpartum haemorrhage.*<br />* This event has been reported for the therapeutic<br />class of SSRIs/ SNRIs.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />□ Do not store above 30&deg;C, protected from light.<br />□ Do not use OXETINE after the expiry date which is<br />stated on the carton and on the blister, after<br />(EXP).Date.<br />Medicines should not be disposed of via wastewater<br />or household waste. Ask your pharmacist how to<br />dispose of medicines no longer required. These<br />measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Fluoxetine. Each<br />OXETINE Film-Coated Tablet contains Fluoxetine<br />20mg as Fluoxetine Hydrochloride.<br />□ The other ingredients are: Maize starch, Lactose,<br />Povidone K29-32, Colloidal Anhydrous Silica,<br />Magnesium Stearate, Hydroxypropyl Methylcelluose<br />Type 2910, Polyethylene Glycol 400, and Titanium<br />Dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                OXETINE 20 Film - Coated Tablet are white to off
white, square shallow biconvex shaped film coated
tablets with “OX 20” debossed on one side and plain
on the other side.
□ Boxes of 10 blistered tablets of OXETINE 20.
□ Boxes of 20 blistered tablets of OXETINE 20.
□ Boxes of 30 blistered tablets of OXETINE 20.
Saudi Arabia: To report any side effect(s): National
Pharmacovigilance Center (NPC): Fax:
+966-11-205-7662, SFDA Call center: 19999, E-mail:
npc.drug@sfda.gov.sa, Website:
https://ade.sfda.gov.sa
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Jordanian pharmaceutical manufacturing co.(P.L.C.|)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>۱. ما هو أكستين و ما هي دواعي استعماله<br />تحتوي أقراص أكستين على المادة الفعالة فلوكستين التي هي<br />واحدة من مجموعة الأدوية التي تسمى المثبطات الانتقائية<br />لاسترداد السيروتونين والتي تستخدم لعلاج الاكتئاب.<br />يستخدم هذا الدواء لعلاج الحالات التالية:<br />البالغين:<br />اضطراب الوسواس القهري □ الاكتئاب النفسي الرئيسي □<br />النهام العصبي: يستخدم أكستين إلى جانب العلاجات □<br />النفسية للتقليل من سلوك الأكل بشكل مفرط والإسهال.<br />الاطفال و المراهقين الذين يبلغون من العمر ثماني سنوات<br />فما فوق:<br />يستخدم لعلاج الاضطراب الاكتئابي المتوسط الى الشديد، إذا<br />٦ جلسات. ينبغي أن - لم يستجب الاكتئاب للعلاج النفسي بعد ٤<br />يقدم أكستين للطفل أوصغار السن المصابين باضطراب<br />الاكتئاب الرئيسي المعتدل إلى الشديد فقط مع العلاج النفسي.<br />طريقة عمل أكستين<br />كل شخص لديه مادة تدعى السيروتينين في الدماغ. الأشخاص<br />الذين يعانون من الاكتئاب أو اضطراب الوسواس القهري أو<br />النهام العصبي لديهم معدلات السيروتينين أقل من الأخرين.<br />ليس مفهوماً تماماً آلية عمل أكستين و مثبطات إعادة<br />امتصاص السيروتينين، لكنه قد يساعد في زيادة معدلات<br />السيروتنين في الدماغ. علاج هذه الحالة تساعدك في أن تكون<br />أفضل.<br />قد تسوء حالتك و تصبح أكثر خطورة في حال عدم إتمام<br />العلاج . قد تحتاج العلاج لعدة أسابيع أو أشهر للتأكد من<br />سلامتك و زوال الأعراض .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال أكستين<br />إذا كنت تعاني من حساسية أكستين أو لأي من المكونات □<br />الأخرى لهذا الدواء (المدرجة في القسم ٦). إذا كنت تعاني<br />من الطفح الجلدي أو حساسية أخرى (مثل الحكة، تورم الشفاه<br />أو الوجه أو ضيق في التنفس)، توقف عن أخذ الأقراص<br />واتصل بطبيبك على الفور.<br />إذا كنت تتناول أدوية أخرى تعرف باسم مثبطات أوكسيديز □<br />مونوامين غير الانتقائية، حيث أنه يمكن أن تحدث ردود فعل<br />خطيرة أو حتى مميتة (مثل إيبرونيازيد الذي يستخدم لعلاج<br />الاكتئاب).<br />العلاج بأكستين يجب أن يبدأ بعد أسبوعين من التوقف عن<br />تناول مثبطات أوكسيديز مونوامين غير الانتقائية . لا تأخذ أي<br />من مثبطات أوكسيديز مونوامين غير الانتقائية لمدة خمس<br />أسابيع على الأقل بعد التوقف عن تناول أكستين .<br />إذا تم وصف أكستين لفترة طويلة و/ أوبجرعة عالية يجب أن<br />يأخذ طبيبك بعين الاعتبار أن تكون الفترة الزمنية أطول. إذا<br />كنت تتناول ميتوبرولول (لعلاج فشل القلب) لأن هناك احتمال<br />متزايد أن ضربات القلب تصبح بطيئة جداً.<br />الاحتياطات عند استعمال أكستين :<br />تحدث الى طبيبك أو الصيدلي قبل تناول أكستين إذا كان أي<br />مما يلي ينطبق عليك:<br />ظهور الحمى، صلابة العضلات أو □ مشاكل بالقلب □<br />رعاش، التغيرات في الحالة العقلية مثل الارتباك، التهيج و<br />الهياج الشديد، قد تعاني من من ما يسمى &quot;متلازمة<br />السيريوتينين&quot; أو &quot; المتلازمة الخبيثة للدواء المضاد للذهان&quot; .<br />على الرغم من أن هذه المتلازمة نادراً ما تحدث إلا انها قد<br />تؤدي إلى الوفاة؛ اتصل بطبيبك على الفور، لأن أكستين<br />يحتاج إلى التوقف.<br />إذا كنت مصاب بالهوس بالوقت الحالي أو في الماضي ، □<br />□ . اتصل بطبيبك على الفور لأن اكستين يحتاج الى التوقف<br />اذا سبق و عانيت من اضطراب النزيف أو ظهور كدمات أو<br />نزيف غير عادي.<br />العلاج المستمر باستخدام الأدوية التي ترقق الدم ( انظر □<br />الصرع و النوبة . إذا □ .( تناول أدوية أخرى مع أكستين<br />كنت تعاني من النوبة أو زيادة في تردد النوبة، اتصل بطبيبك<br />العلاج □ . على الفور لأن أكستين قد يحتاج الى التوقف<br />العلاج المستمر بتاموكسيفين □ . المستمر بالصدمة الكهربائية<br />(لعلاج سرطان الثدي ) (انظر تناول أدوية أخرى مع<br />اكستين).<br />الشعور في التململ أو عدم القدرة على الجلوس أو الوقوف □<br />(تعذر الجلوس ). زيادة جرعة أكستين قد تجعل هذا أسوأ.<br />مرض السكري ( قد يحتاج طبيبك الى ضبط جرعة □<br />مشاكل □ .( الأنسولين أو أي أدوية أخرى مضادة السكري<br />الكبد (قد يحتاج طبيبك الى ضبط الجرعة).<br />انخفاض معدل راحة القلب و/ أو اذا كنت تعاني من فقد □<br />الأملاح نتيجة أسهال شديد لمدة طويلة و قيء او استخدام<br />مدرات البول.<br />العلاج المستمر بمدرات البول، خاصة إذا كنت من كبار □<br />زيادة في ضغط العين . □ . السن<br />أفكار الانتحار وتفاقم الاكتئاب أو اضطراب القلق:<br />إذا كنت تعاني من الاكتئاب و / أو لديك اضطرابات القلق<br />يمكن أن يكون لديك أحياناً أفكار من ايذاء أو قتل نفسك.<br />ويمكن زيادة هذه الحالة عند بداية استخدام مضادات<br />الاكتئاب، لأن هذه الأدوية تستغرق وقتاً طويلاً للعمل، عادة ما<br />تحتاج حوالي أسبوعين ولكن في بعض الأحيان تحتاج وقت<br />أطول.<br />قد تكون أكثر عرضة للتفكير مثل هذا:<br />إذا □ . إذا كان لديك سابقاً أفكار حول قتل أو إيذاء نفسك □<br />كنت من البالغين، أظهرت المعلومات من التجارب السريرية<br />زيادة خطر السلوك الانتحاري في البالغين الذين تقل أعمارهم<br />عن ۲٥ عاماً و يعانون من الحالات النفسية و تمت معالجتهم<br />باستخدام مضادات الاكتئاب.<br />إذا كان لديك أفكار عن إلحاق الضرر أو قتل نفسك في أي<br />وقت، اتصل بطبيبك أواذهب إلى المستشفى على الفور.<br />قد تجد أنه من المفيد أن تخبر أحد الأقارب أو الأصدقاء<br />المقربين أنك مصاب بالاكتئاب أو انك تعاني من اضطراب<br />من القلق، واطلب منهم قراءة هذه النشرة. قد تطلب منهم أن<br />يقولوا لك إذا كانوا يعتقدون أن الاكتئاب أو القلق يزداد سوءاً،<br />أو إذا كانوا قلقين بشأن التغييرات في سلوكك.<br />الاطفال و المراهقين من عمر ۸ سنوات الى ۱۸ سنة:<br />المرضى الذي تقل أعمارهم عن ۱۸ لديهم خطر متزايد من □<br />الآثار الجانبية مثل محاولة الانتحار والأفكار الانتحارية<br />والعداء (في الغالب العدوان والسلوك المعارض والغضب)<br />عند تناولهم هذه الفئة من الأدوية. أكسيتين يجب أن تستخدم<br />فقط في الأطفال والمراهقين الذين تتراوح أعمارهم بين ۸ إلى<br />۱۸ عاما لعلاج نوبات الاكتئاب الرئيسي المعتدلة إلى شديدة<br />(مع العلاج النفسي)، وينبغي أن لا تستخدم لعلاج الحالات<br />الأخرى.<br />بالإضافة إلى ذلك، لا تتوفر سوى معلومات محدودة حول □<br />سلامة أكستين على المدى الطويل على مرحلة النمو والبلوغ<br />والحالة العقلية والعاطفية والسلوكية في هذه الفئة العمرية.<br />على الرغم من هذا، إذا كنت مريضاً دون سن ۱۸ عاماً، قد<br />يصف طبيبك أكستين لنوبات الاكتئاب الرئيسي المعتدلة إلى<br />الشديدة، جنباً إلى جنب مع العلاج النفسي، و يقرر هذا بناءاً<br />على مصلحتك الخاصة. إذا كان طبيبك قد وصف أكستين<br />للمريض دون سن ۱۸ وكنت ترغب في مناقشة هذا، يرجى<br />العودة إلى الطبيب. يجب عليك إبلاغ الطبيب إذا كان أي من<br />الأعراض المذكورة أعلاه تتطور أو تزداد سوءاً عندما يأخذ<br />لا ينبغي استخدام □ . المرضى دون سن ۱۸ عاماً أكستين<br />أكستين في علاج الأطفال الذي تقل أعمارهم عن ۸ سنوات .<br />الإختلال الجنسي<br />أعراض (SSRIs قد تسبب الأدوية مثل أكستين (تسمى<br />الخلل الوظيفي الجنسي (انظر القسم ٤). في بعض الحالات،<br />استمرت هذه الأعراض بعد التوقف عن العلاج.<br />- قد تزيد المثبطات الإنتقائية لإعادة امتصاص السيروتونين<br />خطر حدوث نزيف ما بعد (SSRI/SNRI) والنورايبينفرين<br />الولادة.<br />تناول أدوية اخرى مع أكستين:<br />اخبر طبيبك اوالصيدلي اذا كنت تتناول أوتناولت مؤخراً أو قد<br />تتناول أي أدوية أخرى.<br />لا تتناول أكستين مع:<br />بعض مثبطات أوكسيديز مونوامين غيرالانتقائية التي □<br />تستخدم لمعالجة الاكتئاب. يجب عدم استخدام مثبطات<br />أوكسيديز مونوامين غير الانتقائية مع أكستين لأنه يسبب<br />ردود فعل خطيرة أو مميتة (متلازمة السيرتونين ) (انظر قسم<br />&quot;موانع استخدام أكسيتين&quot;).<br />العلاج باستخدام أكستين يجب ان يبدأ بعد اسبوعين على الأقل<br />من التوقف مثبطات أوكسيديز مونوامين غير الانتقائية (على<br />سبيل المثال ترانيلسيبرومين). لا تتناول مثبطات أوكسيديز<br />مونوامين غير الانتقائية لمدة خمس أسابيع على الأقل بعد<br />التوقف عن تناول أكستين . إذا تم وصف أكستين لفترة<br />طويلة و / أو بجرعة عالية، قد تحتاج إلى فترة أطول من ٥<br />أسابيع ليتم النظر فيها من قبل الطبيب .<br />عند استخدام ميتوبرولول لعلاج فشل القلب، هناك احتمال<br />متزايد أن تصبح ضربات قلبك بطيئة جداً.<br />قد يؤثر أكسيتين على الطريقة التي تعمل بها الأدوية<br />التالية:<br />تاموكسيفين (يستخدم لعلاج سرطان الثدي)، يسبب أكستين □<br />في تغير مستويات الدم لهذا الدواء، مما يؤدي إلى إمكانية<br />الحد من تأثير تاموكسيفين، قد يحتاج طبيبك للنظر<br />في وصف علاج اخر مضاد للاكتئاب.<br />مثبطات مونوامين أوكسوديز و يشمل موكلوبميد، □<br />لنزوليد(مضاد حيوي) ميثيل ثيونينيوم كلوريد (أيضاً يسمى<br />مثيلين بلو(يستخدم لعلاج المنتجات الطبية أو الكيميائية التي<br />يسببها ميتهيموغلوبينية الدم) نظراً لردود الفعل الخطيرة أو<br />المميتة ( ملازمة السيرتونين ). يمكن بدأ العلاج باستخدام<br />فلوكستين بعد يوم من توقف العلاج بمثبطات مونوامين<br />اوكسوديز الانتقائية و لكن قد يرغب الطبيب بمراقبتك بعناية<br />و استخدام جرعة أقل من مثبطات مونوامين اوكسوديز.<br />ميكويتازين (يستخدم للحساسية)، لأن استخدام هذا الدواء □<br />مع أكستين يسبب في زيادة خطر تغيرات النشاط الكهربائي<br />للقلب .<br />الفينيتوين (يستخدم للصرع)، قد يسبب أكستين تغير في □<br />مستويات الدم لهذا الدواء، قد يحتاج طبيبك إلى إدخال<br />الفينيتوين بعناية أكثروعمل الفحوصات عندما تعطى مع<br />أكستين.<br />الليثْيُوم، سيليجيلين، نبته سانت جون، ترامادول (مسكن □<br />ألالم )، التيربيتان (للصداع النصفي ) وتريتوفان، يسبب في<br />زيادة خطر الأصابة بمتلازمة السيروتنين إذا تم أخذهم مع<br />الأكستين فأنه يلزم مراقبة سريرية محكمة و أكثر تكرار.<br />الأدوية التي تأثر على ضربات القلب مثل الفئة الأولى (أ) □<br />والفئة الثالثة من أدوية اضطرابات نظم القلب، أدوية مضاد<br />الذهان (مثل مشتقات فينوثيازين ، بيموزيد ، هالوبريدول)،<br />أدوية مضادات الأكتئاب الثلاثية الحلقات، بعض أدوية<br />مضادات الميكروبات (مثل سبارفلوكساسين،<br />موكسيفلوكساسين، إريثرومايسين ، بنتاميدين) الأدوية<br />المضادة للملاريا و خاصة هالوفانترين أو بعض الأدوية<br />المضادة للهيستامين (أستيميزول، ميزولاستين)، لأن تناول<br />واحد او أكثر من هذه الأدوية مع أكستين يتسبب في زيادة<br />خطر تغير النشاط الكهربائي للقلب.<br />الأدوية المضادة للتخثر (مثل الوارفرين )، الأدوية □<br />المضادة للالتهابات غيرسترودية (مثل ايبوبروفن،<br />ديكلوفيناك) أسبرين و بعض الأدوية الأخرى التي ترقق الدم<br />(بما في ذالك كلوزابين الذي يستخدم لعلاج بعض<br />الاضطرابات النفسية ). قد يغير الأكستين تأثير هذه الأدويه<br />على الدم. إذا بدأت أو توقفت عن تناول الأكستين خلال أخذك<br />للورافرين سيحتاج طبيبك لإجراء فحوصات معينة، و ضبط<br />جرعتك و فحصك بشكل متكرر.<br />سيبروهيبتادين (يستخدم للحساسية )، يمكن ان يقلل فعالية □<br />الأكستين .<br />الأدوية التي تخفض مستويات الصوديوم في الدم (يشمل □<br />الأدوية التي تسبب في زيادة التبول، ديزمُوبرِيسِين،<br />كاربامازيبين و أوكسكاربازيبين)، لأن هذه الادوية قد تزيد<br />من خطر انخفاض مستويات الصوديوم في الدم عندما تؤخذ<br />مع أكسيين.<br />مضادات الاكتئاب مثل مضادات الاكتئاب ثلاثية الحلقات □<br />ومثبطات امتصاص السيروتونين الانتقائية أو البوبروبيون أو<br />الميفلوكين أو الكلوروكين (المستخدمة لعلاج الملاريا) أو<br />الترامادول (الذي يستخدم لعلاج الألم الشديد) أو مضادات<br />الذهان مثل الفينوثيازين أو البوتيروفينونيس؛ لأن أكستين قد<br />يزيد من خطر النوبة عندما يؤخذ مع هذه الأدوية.<br />فليكاينيد، بروبافينون، نيبيفولول أو إنكاينيد (لمشاكل في □<br />القلب)، كاربامازيبين (للصرع)، أتوموكسيتين أو مضادات<br />الاكتئاب ثلاثية الحلقات (على سبيل المثال إيميبرامين،<br />ديسيبرامين وأميتريبتيلين) أو ريسبيريدون (للفصام). لأن<br />أكستين ربما يغير مستويات الدم من هذه الأدوية، قد يحتاج<br />طبيبك لخفض جرعتها عندما تعطى مع أكستين.<br />تتناول أكستين مع الطعام، الشراب والكحول:<br />يمكنك ان تناول أكستين مع أو بدون الطعام كما تفضل . □<br />يجب عليك تجنب الكحول أثناء تناولك لهذا الدواء . □<br />الحمل، الرضاعة والخصوبة:<br />إذا كنت حاملاً أو مرضعة، أو تعتقدين بأنك حامل أو<br />تخططين للأنجاب، اطلبي من طبيبك أو الصيدلي تقديم<br />المشورة قبل تناول هذا الدواء.<br />الحمل:<br />تحدثي مع طبيبك في أقرب وقت ممكن إذا كنت حاملاً، أو من<br />المحتمل أن تصبحي حاملاً أو إذا كنت تخططين للإنجاب.<br />الأطفال الذين أخذت أمهاتهم فلوكستين خلال الأشهر الأولى<br />من الحمل، كانت هناك بعض الدراسات التي تصف زيادة<br />خطر العيوب الخلقية التي تؤثر على القلب. ويولد حوالي ۱<br />من ۱۰۰ طفل مع عيب في القلب. وزاد هذا إلى حوالي ۲ من<br />۱۰۰ طفل في الأمهات اللائي أخذن فلوكستين.<br />عندما تؤخذ الأدوية مثل فلوكستين أثناء الحمل، وخاصة في<br />الأشهر الثلاثة الأخيرة من الحمل، قد تزيد من خطر حدوث<br />حالة خطيرة في الأطفال، تسمى ارتفاع ضغط الدم الرئوي<br />المستمر، مما يجعل الطفل يتنفس بشكل أسرع ويظهر مزرق.<br />وعادة ما تبدأ هذه الأعراض خلال ال ۲٤ ساعة الأولى بعد<br />ولادة الطفل. إذا حدث ذلك لطفلك، فيجب عليك الاتصال<br />بالقابلة و / أو الطبيب فوراً.<br />ومن الأفضل عدم استخدام هذا العلاج خلال فترة الحمل ما لم<br />تكن الفائدة تفوق المخاطر المحتملة. وبالتالي، قد تقرر أنت<br />وطبيبك التوقف تدريجياً عن تناول أكسيتين أثناء أو قبل<br />الحمل. ويعتمد ذالك على الظروف الخاصة بك، قد يقترح<br />طبيبك أنه من الأفضل بالنسبة لك الاستمرارعلى تناول<br />أكستين.<br />ينبغي توخي الحذر عند استخدامها أثناء الحمل، وخاصة<br />خلال فترة الحمل المتأخرة أو قبل الولادة مباشرة منذ أن تم<br />الإبلاغ عن الآثار التالية في الأطفال حديثي الولادة: التهيج،<br />الهزة، ضعف العضلات، البكاء المستمر، وصعوبة في المص<br />أو في النوم.<br />الرضاعة:<br />يتم إفرز فلوكستين في حليب الأم ويمكن أن يسبب آثاراً<br />جانبية في حالة الإرضاع الطبيعي للطفل. يجب عليك<br />الإرضاع عند الضرورة، فأن طبيبك سوف يصف لك جرعة<br />أقل من فلوكستين.<br />الخصوبة:<br />قد أظهر فلوكستين أنه يقلل من نوعية الحيوانات المنوية في<br />الدراسات الحيوانية. ومن الناحية النظرية، يمكن أن يؤثر ذلك<br />على الخصوبة، ولكن لم يلاحظ حتى الآن التأثير على<br />خصوبة الإنسان.<br />* المعلومات الرصدية تشير إلى إزدياد خطر حدوث نزيف ما<br />بعد الولادة (أقل من ۲ ضعف) بعد التعرض لأدوية<br />خلال شهر قبل الولادة. SSRI/SNRI<br />القيادة أو أستخدام الألات :<br />الادوية النفسية مثل أكستين يمكن أن تأثرعلى قررارتك. لا<br />تقود او تسخدم الآلات حتى تعرف تأثير الأكسيتين عليك.<br />معلومات هامة حول بعض مكونات أكستين:<br />تحتوي أقراص أكستين على لاكتوز (نوع من السكريات). إذا<br />أخبرك طبيبك بأن لديك عدم القدرة على تحمل بعض<br />السكريات، فإن عليك الاتصال بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عليك أن تتناول الدواء كما أخبرك طبيبك تماماً .يجب<br />عليك مراجعة طبيبك أو الصيدلي اذا لم تكن متأكداً. لا تتناول<br />أقراص أكثر من التي وصفها لك الطبيب . ابتلع الأقراص مع<br />كوب من الماء .لا تمضغ الأقراص.<br />البالغين:<br />الجرعة الموصى بها :<br />الاكتئاب: الجرعة الموصى بها هي قرص واحد ( ۲۰ ملغم) □<br />يومياً. سيقوم طبيبك بمراجعة وضبط الجرعة إذا لزم الأمر<br />في غضون ۳ إلى ٤ أسابيع من بدء العلاج. إذا لزم الأمر،<br />يمكن زيادة الجرعة تدريجياً إلى الحد الأقصى و هي ۳<br />أقراص ( ٦۰ ملغم) يومياً. وينبغي زيادة الجرعة بعناية<br />لضمان حصولك على أقل جرعة فعالة. قد لا تشعر على نحو<br />أفضل على الفور عند البدء بتناول الدواء لعلاج الاكتئاب. هذا<br />هو المعتاد لأن تحسن في أعراض الاكتئاب قد لا تحدث إلا<br />بعد الأسابيع القليلة الأولى. وينبغي علاج المرضى الذين<br />يعانون من الاكتئاب لمدة لا تقل عن ٦أشهر.<br />النهام العصبي: الجرعة التي ينصح بها ثلاثة أقراص ( ٦۰ □<br />ملغم) يومياً .<br />اضطراب الوسواس القهري: الجرعة الموصى بها هي □<br />قرص واحد ( ۲۰ ملغم) يومياً. سيقوم طبيبك بمراجعة وتعديل<br />الجرعة عند الضرورة بعد أسبوعين من العلاج. إذا لزم<br />الأمر، يمكن زيادة الجرعة تدريجياً إلى الحد الأقصى هي ۳<br />أقراص ( ٦۰ ملغم) يومياً. إذا لم يتم تسجيل أي تحسن خلال<br />۱۰ أسابيع، سيقوم الطبيب بإعادة النظر في العلاج.<br />الاستخدام في الأطفال و المراهقين الذين تتراوح اعمارهم ما<br />بين ۸ الى ۱۸ سنة و يعانون من الاكتئاب :<br />ينبغي أن يبدأ العلاج وأن يشرف عليه أخصائي. جرعة البدء<br />هي ۱۰ ملغم في اليوم. بعد أسبوع إلى أسبوعين، قد يقوم<br />طبيبك زيادة الجرعة إلى ۲۰ ملغم يومياً. ينبغي زيادة الجرعة<br />بعناية لضمان حصولك على أقل جرعة فعالة. قد يحتاج<br />الأطفال ذوي الوزن المنخفض إلى جرعات أقل، إذا كان<br />هناك استجابة مرضية للعلاج، طبيبك سوف يعيد النظر في<br />الحاجة الى استمرار العلاج بعد ٦ أشهر. يجب إعادة النظر<br />في المعالجة إذا لم تحصل على فوائد سريرية خلال ۹ أسابيع<br />كبار السن:<br />سوف يقوم طبيبك بزيادة الجرعة مع مزيد من الحذر، يجب<br />أن لا تزيد الجرعة اليومية قرصين ( ٤۰ ملغم). الجرعة<br />القصوى هي ۳ أقراص ( ٦۰ ملغم) يومياً.<br />قصور الكبد :<br />إذا كان لديك مشكلة في الكبد أو كنت تستخدم أدوية أخرى قد<br />تؤثر على أكسيتين، قد يقرر طبيبك أن يصف لك جرعة أقل<br />أو يخبرك باستخدام أكستين يوماً بعد يوم.<br />الجرعة الزائدة من أكستين :<br />إذا تناولت الكثير من الاقراص، اذهب الى قسم الطوارىء □<br />خذ علبة □ . في أقرب مستشفى أو أخبر طبيبك على الفور<br />الأكستين معك إذا كنت تستطيع .<br />قد تشمل أعراض الجرعة الزائدة الغثيان، التقيؤ، النوبات،<br />مشاكل في القلب (مثل ضربات القلب غير المنتظمة والسكتة<br />القلبية)، مشاكل في الرئة والتغيير في الحالة النفسية تتراوح<br />التي بين الهيجان والغيبوبة.<br />نسيان تناول جرعة أكستين:<br />إذا فوت الجرعة، لا تقلق. خذ الجرعة التالية في اليوم □<br />التالي في الوقت المعتاد. لا تأخذ جرعة مضاعفة لتعويض<br />تناول الدواء في نفس الوقت كل يوم قد □ . الجرعة المنسية<br />يساعدك على تذكر أن تأخذه بانتظام.<br />قد تلاحظ الآثار التالية (آثار الانسحاب) عند التوقف عن<br />تناول أكسيتين: الدوخة، وخز مثل الدبابيس والإبر.<br />اضطرابات النوم (أحلام اليقظة، والكوابيس، وعدم القدرة<br />على النوم). والشعور بعدم الارتياح أو تحريكها، التعب أو<br />الضعف غير العادي. الشعور بالقلق. الغثيان / التقيؤ (الشعور<br />بالمرض). الارتعاش، الصداع.<br />معظم الناس يجدون أن أعراض وقف أكستين خفيفة وتختفي<br />في غضون أسابيع قليلة. إذا واجهت أعراض عند التوقف عن<br />العلاج، اتصل بطبيبك.<br />عند التوقف عن أخذك لأكستين، سوف يساعدك طبيبك على<br />تقليل الجرعة ببطء على مدى أسبوع أو اسبوعين وهذا من<br />شأنه أن يساعد على تقليل فرصة آثار الانسحاب.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل<br />طبيبك أو الصيدلاني</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كغيره من الادوية، فقد يسبب أكستين أعراضاً جانبية، بالرغم<br />من أنها لا تحدث للجميع.<br />إذا كان لديك أفكار عن إلحاق الضرر أو قتل نفسك في أي □<br />وقت، اتصل بطبيبك أو اذهب إلى المستشفى على الفور.<br />( (انظر إلى قسم ۲<br />إذا عانيت من طفح جلدي أو رد فعل تحسسي مثل الحكة □<br />وتورم الشفاه / اللسان أوصفير/ ضيق التنفس، توقف عن<br />تناول الأقراص على الفور وأخبر طبيبك فوراً.<br />إذا كنت تشعر بالتململ ولا يمكنك الجلوس أو الوقوف □<br />(أكاثيسيا). فإن زيادة جرعة أكسيتين قد تجعلك تشعر أسوأ.<br />إذا كنت تشعر بهذا، اتصل بطبيبك.<br />أخبر طبيبك على الفور إذا بدأت بشرتك في التحول إلى □<br />اللون الأحمر أو بدأ جلدك في التقشر. هذا أمر نادر جداً.<br />الأعراض الجانبية الشائعة (تؤثر على أكثرمن شخص واحد<br />من كل عشرة أشخاص) هي الأرق والصداع والإسهال<br />والشعور بالمرض (الغثيان) والتعب.<br />بعض المرضى لديهم :<br />مجموعة من الأعراض (المعروفة باسم &quot;متلازمة □<br />السيروتونين&quot;) بما في ذلك الحمى غير المبررة مع سرعة<br />التنفس أو معدل ضربات القلب، والتعرق، وصلابة العضلات<br />أو ارتعاش، والارتباك، والهياج الشديد أو النعاس (نادراً<br />مشاعر الضعف، النعاس أو الارتباك في الغالب □ .( فقط<br />الانتصاب □ . عند كبار السن الذين يتناولون مدرات البول<br />مشاكل □ . التهيج والهياج الشديد □ . لفترات طويلة ومؤلمة<br />القلب، مثل سرعة ضربات القلب أو عدم انتظام ضربات<br />القلب، الإغماء، الانهيار أو الدوخة عند الوقوف والتي تشير<br />إلى عمل غير طبيعي لمعدل ضربات القلب.<br />إذا کان لديك أي من الأعراض الجانبية المذکورة أعلاه،<br />فيجب عليك إخبار طبيبك على الفور.<br />كما تم الإبلاغ عن الآثار الجانبية التالية في المرضى الذين<br />يتناولون أكستين:<br />الأعراض الجانبية الشائعة (تؤثر على شخص واحد من<br />أصل عشرة أشخاص):<br />العصبية و القلق □ . عدم شعور بالجوع، و فقدان الوزن □<br />الشعور بالتوتر . □ . عدم الراحة، وضعف التركيز □<br />انخفاض الدافع الجنسي أو المشاكل الجنسية (بما في ذلك □<br />مشاكل □ .( صعوبة الحفاظ على الانتصاب للنشاط الجنسي<br />الدوخة. □ . ( النوم ( أحلام غير عادية، التعب أو النعاس<br />حركات اهتزاز غير قابلة □ . تغير في حاسة الذوق □<br />ضربات القلب غير □ . عدم وضوح الرؤية □ . للضبط<br />عسر □ . تثاؤب □ . احمرار □ . المنتظمة و السريعة<br />طفح جلدي، شرى، الحكة □ جفاف الفم □ الهضم و القيء<br />تمرير البول بشكل □ . ألم المفاصل □ . زيادة التعرق □<br />شعور الارتعاش □ . نزيف المهبل غير المبرر □ . متكرر<br />او القشعريرية .<br />الأعراض الجانبية غير الشائعة (تؤثر على شخص واحد من<br />أصل ۱۰۰ شخص):<br />مزاج □ . التفكير الغريب □ . شعور منفصل عن نفسك □<br />المشاكل الجنسية، بما في ذلك □ . عالي بشكل غير طبيعي<br />مشاكل النشوة الجنسية، أحيانا تستمر بعد التوقف عن العلاج.<br />صريف (صك) □ . أفكار الانتحار أو اضرار بنفسك □<br />ارتعاش العضلات ،حركات لا أرادية أو مشاكل □ . الاسنان<br />توسع بؤبؤ □ . ضعف الذاكرة □ . بالتوازن و التنسيق<br />ضيق □ . انخفاض ضغط الدم □ . رنين في الأذن □ . العين<br />تساقط □ . صعوبة في البلع □ . نزيف الأنف □ في التنفس<br />الكدمات غير □ . زيادة الميل الى الكدمات □ . الشعر<br />صعوبة تمرير البول. □ . الزكام □ المبررة أو النزيف<br />نتائج غير طبيعية لفحص □ . الشعوربالدفء أو البرد □<br />الكبد.<br />الأعراض الجانبية النادرة (تؤثر على شخص واحد من<br />أصل ۱۰۰۰ شخص) :<br />انخفاض الصفائح □ . انخفاض نسبة الملح في الدم □<br />انخفاض □ . الدموية، مما يزيد من خطر النزيف او الكدمات<br />السلوك البري غير المنطقي. □ . عدد كريات الدم البيضاء<br />ارتباك. □ . هجمات الذعر □ . هياج □ هلوسة □<br />التهاب الاوعية □ . نوبات □ . التأتأة □ سلوك عدواني □<br />انتفاخ سريع للأنسجة حول الرقبة و الوجه و الفم □ . الدموية<br />مشاكل □ . الكبد الوبائي □ . ألم في المرىء □ . أو الحلق<br />ألم في العضلات. □ . الحساسية لأشعة الشمس □ . الرئة<br />افراز حليب الثدي. □ . مشاكل التبول □<br />كسور العظام - لوحظ وجود خطر متزايد من كسور العظام<br />لدى المرضى الذين يتناولون هذا النوع من الأدوية.<br />معظم هذه الآثار الجانبية من المرجح أن تختفي مع استمرار<br />العلاج.<br />۱۸ سنة) بالإضافة إلى الآثار - في الأطفال والمراهقين ( ۸<br />الجانبية المحتملة المذكورة أعلاه، قد يبطئ أكستين النمو أو<br />ربما يؤخر النضج الجنسي. كما تم الإبلاغ عن السلوكيات<br />المرتبطة بالانتحار (محاولة الانتحار والأفكار الانتحارية)،<br />والعداء، والهوس، ونزيف الأنف عادة في الأطفال.<br />أعراض جانبية غير معروفة:<br />نزيف ما بعد الولادة * □<br />* تم الإبلاغ عن هذا العرض للفئة العلاجية لأدوية<br />.SSRI/SNRI</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>. ظروف تخزين أكستين<br />لا يحفظ بدرجة □ . يحفظ بعيداً عن متناول الأطفال □<br />حرارة أعلى من ۳۰ م&deg;، يحفظ بعيداً عن الضوء .<br />لا ينبغي استعمال أكستين بعد تاريخ انتهاء الصلاحية □<br />الموجود على العلبة و على شريط الدواء .<br />لا ينبغي التخلص من الأدوية خلال مياه الصرف الصحي أو<br />المنزلي. اسأل الصيدلي عن كيفية التخلص من الأدوية التي<br />لم تعد مطلوبة .سوف تساعد هذه الاجراءات على حماية<br />البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />ما هي محتويات أكستين :<br />المادة الفعالة هي فلوكستين، كل قرص من أقراص أكستين<br />يحتوي على ۲۰ ملغم فلوكستين على هيئة فلوكستين<br />هيدروكلوريد.<br />۳۲- المكونات الاخرى هي: نشا الذرة ،لاكتوز، بوفيدون ۲۹<br />سيليكا غروية لا مائية، ستيارات المغنيزيوم ، ، k<br />هيدروكسي بروبيل ميثيل سيلولوز نوع ۲۹۱۰ ، بولي إثيلين<br />جلايكول ٤۰۰ ، ثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي فلوكستين، كل قرص من أقراص أكستين<br />يحتوي على ۲۰ ملغم فلوكستين على هيئة فلوكستين<br />هيدروكلوريد.<br />۳۲- المكونات الاخرى هي: نشا الذرة ،لاكتوز، بوفيدون ۲۹<br />سيليكا غروية لا مائية، ستيارات المغنيزيوم ، ، k<br />هيدروكسي بروبيل ميثيل سيلولوز نوع ۲۹۱۰ ، بولي إثيلين<br />جلايكول ٤۰۰ ، ثاني أكسيد التيتانيوم.<br />ما هو الشكل الصيدلاني لأكستين و وصفه و حجم عبوته:<br />أقراص أكستين ۲۰ هي أقرا ص مغلفة بيضاء إلى سكرية □<br />OX&quot; اللون، مربعة، مسطحة، ثنائية التحدب منقوش عليها<br />20 &quot; من جانب واحد و جلية من الجانب الأخر.<br />علب تحتوي على ۱۰ أقراص من أقراص أكستين ۲۰ □<br />المحفوظة في أشرطة.<br />علب تحتوي على ۲۰ قرص من أقراص أكستين ۲۰ □<br />المحفوظة في أشرطة.<br />علب تحتوي على ۳۰ قرص من أقراص أكستين ۲۰ □<br />المحفوظة في أشرطة.<br />المملكة العربية السعودية: للإبلاغ عن الأعراض الجانبية:<br />المركزالوطني للتيقظ: فاكس: ۰۰۹٦٦۱۱۲۰٥۷٦٦۲ ، مركز<br />،۱۹۹۹۹:(SFDA) اتصال الهيئة العامة للغذاء والدواء<br />الموقع ،npc.drug@sfda.gov.sa : البريد الإلكتروني<br />https://ade.sfda.gov.sa : الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الاردنية لانتاج الادوية المساهمة العامة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تشرين الثاني 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OXETINE  20 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient: 

20 mg Fluoxetine as Fluoxetine Hydrochloride

Inactive ingredients:

Ingredient	mg/ Tablet
Maize starch	64
Lactose	82.30
Povidon K29-32	6
Colloidal Anhydrous Silica	2
Magnesium Stearate	3
Hydroxypropyl Methylcelluose Type 2910	4.52
Polyethylene Glycol 400	0.48
Titanium Dioxide	1.92

      *For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to off white, square shallow biconvex shaped film coated tablets with
 “OX 20” debossed on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults:</u></p><p>&sect;&nbsp; Major depressive episodes.</p><p>&sect;&nbsp; Obsessive-compulsive disorder.</p><p>&sect;&nbsp; Bulimia nervosa: <strong>OXETINE</strong> is indicated as a complement of psychotherapy for the reduction of binge-eating and purging activity.</p><p><u>Children and Adolescents Aged 8 Years and Above:</u></p><p>Moderate to severe major depressive episode, if depression is unresponsive to psychological therapy after 4-6 sessions. Antidepressant medication should be offered to a child or young person with moderate to severe depression only in combination with a concurrent psychological therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Route of administration: Oral &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Adults:</u></p><p>&sect;&nbsp; Major depressive episodes</p><p>Adults and the elderly: The recommended dose is 20mg daily. Dosage should be reviewed and adjusted if necessary, within 3 to 4 weeks of initiation of therapy and thereafter as judged clinically appropriate. Although there may be an increased potential for undesirable effects at higher doses, in some patients, with insufficient response to 20mg, the dose may be increased gradually up to a maximum of 60 mg (see section 5.1). Dosage adjustments should be made carefully on an individual patient basis, to maintain the patients at the lowest effective dose.</p><p>Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms.</p><p>&sect;&nbsp; Obsessive-compulsive disorder</p><p>Adults and the elderly: The recommended dose is 20mg daily. Although there may be an increased potential for undesirable effects at higher doses, in some patients, if after two weeks there is insufficient response to 20mg, the dose may be increased gradually up to a maximum of 60mg.</p><p>If no improvement is observed within 10 weeks, treatment with Fluoxetine should be reconsidered. If a good therapeutic response has been obtained, treatment can be continued at a dosage adjusted on an individual basis. While there are no systematic studies to answer the question of how long to continue Fluoxetine treatment, OCD is a chronic condition and it is reasonable to consider continuation beyond 10 weeks in responding patients. Dosage adjustments should be made carefully on an individual patient basis, to maintain the patient at the lowest effective dose. The need for treatment should be reassessed periodically. Some clinicians advocate concomitant behavioural psychotherapy for patients who have done well on pharmacotherapy.</p><p>Long-term efficacy (more than 24 weeks) has not been demonstrated in OCD.</p><p>&sect;&nbsp; Bulimia nervosa:</p><p>Adults and the elderly: A dose of 60mg/day is recommended. Long-term efficacy (more than 3 months) has not been demonstrated in bulimia nervosa.</p><p>All indications: The recommended dose may be increased or decreased. Doses above 80mg/day have not been systematically evaluated.</p><p><u>Paediatric population </u></p><p>Children and adolescents aged 8 years and above (moderate to severe major depressive episode):</p><p>Treatment should be initiated and monitored under specialist supervision. The starting dose is 10mg/day. Dose adjustments should be made carefully, on an individual basis, to maintain the patient at the lowest effective dose.</p><p>After one to two weeks, the dose may be increased to 20mg/day. Clinical trial experience with daily doses greater than 20mg is minimal. There is only limited data on treatment beyond 9 weeks.</p><p>Lower-weight children: Due to higher plasma levels in lower-weight children, the therapeutic effect may be achieved with lower doses (see section 5.2).</p><p>For paediatric patients who respond to treatment, the need for continued treatment after 6 months should be reviewed. If no clinical benefit is achieved within 9 weeks, treatment should be reconsidered.</p><p><u>Elderly patients: </u></p><p>Caution is recommended when increasing the dose, and the daily dose should generally not exceed 40mg. Maximum recommended dose is 60mg/day.</p><p><u>Hepatic impairment: </u></p><p>A lower or less frequent dose (e.g., 20mg every second day) should be considered in patients with hepatic impairment (see section 5.2), or in patients where concomitant medication has the potential for interaction with <strong>OXETINE</strong> (see section 4.5).</p><p>Withdrawal symptoms seen on discontinuation of Fluoxetine: Abrupt discontinuation should be avoided. When stopping treatment with Fluoxetine the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see section 4.4 and section 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p><strong>Method of administration:</strong></p><p>&sect;&nbsp; For oral administration.</p><p>&sect;&nbsp; Fluoxetine may be administered as a single or divided dose, during or between meals.</p><p>When dosing is stopped, active drug substances will persist in the body for weeks. This should be borne in mind when starting or stopping treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Fluoxetine is contraindicated in combination with a non-selective MAOI (e.g iproniazid). 
                      Fluoxetine is contra-indicated in combination with metoprolol used in cardiac 
    failure (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect;&nbsp; Paediatric population - Children and adolescents under 18 years of age: Suicide-related behaviours (suicide attempt and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. <strong>OXETINE</strong> should only be used in children and adolescents aged 8 to 18 years for the treatment of moderate to severe major depressive episodes and it should not be used in other indications. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, only limited evidence is available concerning long-term effect on safety in children and adolescents, including effects on growth, sexual maturation and cognitive, emotional and behavioural developments (see section 5.3).</p><p>In a 19-week clinical trial, decreased height and weight gain was observed in children and adolescents treated with fluoxetine (see section 5.1). It has not been established whether there is an effect on achieving normal adult height. The possibility of a delay in puberty cannot be ruled out (see sections 5.3 and 4.8). Growth and pubertal development (height, weight, and TANNER staging) should therefore be monitored during and after treatment with fluoxetine. If either is slowed, referral to a paediatrician should be considered.</p><p>In paediatric trials, mania and hypomania were commonly reported (see section 4.8). Therefore, regular monitoring for the occurrence of mania/hypomania is recommended. Fluoxetine should be discontinued in any patient entering a manic phase.</p><p>It is important that the prescriber discusses carefully the risks and benefits of treatment with the child/young person and/or their parents.</p><p>&sect;&nbsp; Suicide/suicidal thoughts or clinical worsening: Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>Other psychiatric conditions for which fluoxetine is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>Patients with a history of suicide-related events, those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressants drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>Close supervision of patients, and in particular those at high risk, should accompany drug therapy especially in early treatment, and following dose changes.</p><p>&sect;&nbsp; Cardiovascular Effects: Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period (see sections 4.5, 4.8 and 4.9).</p><p>Fluoxetine should be used with caution in patients with conditions such as congenital long QT syndrome, a family history of QT prolongation or other clinical conditions that predispose to arrhythmias (e.g., hypokalemia and hypomagnesemia, bradycardia, acute myocardial infarction or uncompensated heart failure) or increased exposure to fluoxetine (e.g., hepatic impairment)), or concomitant use with medicinal products known to induce QT prolongation and/or torsade de pointes (see section 4.5).</p><p>If patients with stable cardiac disease are treated, an ECG review should be considered before treatment is started. If signs of cardiac arrhythmia occur during treatment with fluoxetine, the treatment should be withdrawn and an ECG should be performed.</p><p>&sect;&nbsp; Irreversible, non-selective monoamine oxidase inhibitors (e.g. iproniazid): Some cases of serious and sometimes fatal reactions have been reported in patients receiving an SSRI in combination with an irreversible, non-selective monoamine oxidase inhibitor (MAOI).</p><p>These cases presented with features resembling serotonin syndrome (which may be confounded with (or diagnosed as) neuroleptic malignant syndrome). Cyproheptadine or dantrolene may benefit patients experiencing such reactions. Symptoms of a drug interaction with a MAOI include: hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes that include confusion, irritability and extreme agitation progressing to delirium and coma.</p><p>Therefore, fluoxetine is contra-indicated in combination with an irreversible, non-selective MAOI (see section 4.3). Because of the two weeks-lasting effect of the latter, treatment of fluoxetine should only be started 2 weeks after discontinuation of an irreversible, non-selective MAOI. Similarly, at least 5 weeks should elapse after discontinuing fluoxetine treatment before starting an irreversible, non-selective MAOI.</p><p>&sect;&nbsp; Serotonin syndrome or neuroleptic malignant syndrome-like events: On rare occasions, development of a serotonin syndrome or neuroleptic malignant syndrome-like events have been reported in association with treatment of fluoxetine, particularly when given in combination with other serotonergic (among others, L-tryptophan) and/or neuroleptic drugs. As these syndromes may result in potentially life-threatening conditions, treatment with fluoxetine should be discontinued if such events (characterised by clusters of symptoms, such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes, including confusion, irritability, extreme agitation, progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated.</p><p>&sect;&nbsp; Mania: Antidepressants should be used with caution in patients with a history of mania/hypomania. As with all antidepressants, fluoxetine should be discontinued in any patient entering a manic phase.</p><p>&sect;&nbsp; Haemorrhage: There have been reports of cutaneous bleeding abnormalities, such as ecchymosis and purpura with SSRIs. Ecchymosis has been reported as an infrequent event during treatment with fluoxetine. Other haemorrhagic manifestations (e.g., gynaecological haemorrhages, gastro-intestinal bleedings and other cutaneous or mucous bleedings) have been reported rarely. Caution is advised in patients taking SSRIs, particularly in concomitant use with oral anticoagulants, drugs known to affect platelet function (e.g., atypical antipsychotics, such as clozapine, phenothiazines, most TCAs, aspirin, NSAIDs), or other drugs that may increase risk of bleeding, as well as in patients with a history of bleeding disorders.</p><p>&sect;&nbsp; Seizures: Seizures are a potential risk with antidepressant drugs. Therefore, as with other antidepressants, fluoxetine should be introduced cautiously in patients who have a history of seizures. Treatment should be discontinued in any patient who develops seizures or where there is an increase in seizure frequency. Fluoxetine should be avoided in patients with unstable seizure disorders/epilepsy and patients with controlled epilepsy should be carefully monitored.</p><p>&sect;&nbsp; Electroconvulsive therapy (ECT): There have been rare reports of prolonged seizures in patients on fluoxetine receiving ECT treatment; therefore, caution is advisable.</p><p>&sect;&nbsp; Tamoxifen: Fluoxetine, a potent inhibitor of CYP2D6, may lead to reduced concentrations of endoxifen, one of the most important active metabolites of tamoxifen. Therefore, fluoxetine should whenever possible be avoided during tamoxifen treatment (see section 4.5).</p><p>&sect;&nbsp; Akathisia/psychomotor restlessness: &nbsp;The use of fluoxetine has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move, often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p>&sect;&nbsp; Diabetes: In patients with diabetes, treatment with an SSRI may alter glycaemic control. Hypoglycaemia has occurred during therapy with fluoxetine and hyperglycaemia has developed following discontinuation. Insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p>&sect;&nbsp; Hepatic/Renal function: Fluoxetine is extensively metabolised by the liver and excreted by the kidneys. A lower dose, e.g., alternate day dosing, is recommended in patients with significant hepatic dysfunction. When given fluoxetine 20mg/day for 2 months, patients with severe renal failure (GFR &lt;10ml/min) requiring dialysis showed no difference in plasma levels of fluoxetine or norfluoxetine compared to controls with normal renal function.</p><p>&sect;&nbsp; Rash and allergic reactions: Rash, anaphylactoid events and progressive systemic events, sometimes serious (involving skin, kidney, liver or lung), have been reported. Upon the appearance of rash or of other allergic phenomena for which an alternative aetiology cannot be identified, fluoxetine should be discontinued.</p><p>&sect;&nbsp; Weight loss: Weight loss may occur in patients taking fluoxetine, but it is usually proportional to baseline body weight.</p><p>&sect;&nbsp; Withdrawal symptoms seen on discontinuation of SSRI treatment: Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials, adverse events seen on treatment discontinuation occurred in approximately 60% of patients in both the fluoxetine and placebo groups. Of these adverse events, 17% in the fluoxetine group and 12% in the placebo group were severe in nature.</p><p>The risk of withdrawal symptoms may be dependent on several factors, including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), asthenia, agitation or anxiety, nausea and/or vomiting, tremor, and headache are the most commonly reported reactions. Generally, these symptoms are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment. Generally, these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that fluoxetine should be gradually tapered when discontinuing treatment over a period of at least one to two weeks, according to the patient&#39;s needs.</p><p>&sect;&nbsp; Mydriasis: Mydriasis has been reported in association with fluoxetine; therefore, caution should be used when prescribing fluoxetine in patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma.</p><p>&sect;&nbsp; SSRIs/ SNRIs may increase the risk of postpartum haemorrhage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect;&nbsp; Half-life: The long elimination half-lives of both fluoxetine and norfluoxetine should be borne in mind (see section 5.2) when considering pharmacodynamic or pharmacokinetic drug interactions (e.g., when switching from fluoxetine to other antidepressants).</p><p><u>Contra-indicated combinations </u></p><ul><li>Irreversible, non-selective monoamine oxidase inhibitors (e.g. iproniazid): Some cases of serious and sometimes fatal reactions have been reported in patients receiving an SSRI in combination with an irreversible, non-selective monoamine oxidase inhibitor (MAOI).</li><li>These cases presented with features resembling serotonin syndrome (which may be confounded with [or diagnosed as] neuroleptic malignant syndrome). Cyproheptadine or dantrolene may benefit patients experiencing such reactions. Symptoms of a drug interaction with a MAOI include: hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes that include confusion, irritability and extreme agitation progressing to delirium and coma.</li><li>Therefore, fluoxetine is contra-indicated in combination with an irreversible, non-selective MAOI (see section 4.3). Because of the two weeks-lasting effect of the latter, treatment of fluoxetine should only be started 2 weeks after discontinuation of an irreversible, non-selective MAOI. Similarly, at least 5 weeks should elapse after discontinuing fluoxetine treatment before starting an irreversible, non-selective MAOI.</li><li>Metoprolol used in cardiac failure: risk of metoprolol adverse events, including excessive bradycardia, may be increased because of an inhibition of its metabolism by fluoxetine (see section 4.3).</li><li>Not recommended combinations</li><li>Tamoxifen: Pharmacokinetic interaction between CYP2D6 inhibitors and tamoxifen, showing a 65-75 % reduction in plasma levels of one of the more active forms of the tamoxifen, i.e. endoxifen, has been reported in the literature. Reduced efficacy of tamoxifen has been reported with concomitant usage of some SSRI antidepressants in some studies. As a reduced effect of tamoxifen cannot be excluded, co-administration with potent CYP2D6 inhibitors (including fluoxetine) should whenever possible be avoided (see section 4.4).</li><li>Alcohol: In formal testing, fluoxetine did not raise blood alcohol levels or enhance the effects of alcohol. However, the combination of SSRI treatment and alcohol is not advisable.</li><li>MAOI-A including linezolid and methylthioninium chloride (methylene blue): Risk of serotonin syndrome including diarrhoea, tachycardia, sweating, tremor, confusion or coma. If the concomitant use of these active substances with fluoxetine cannot be avoided, close clinical monitoring should be undertaken and the concomitant agents should be initiated at the lower recommended doses (see section 4.4).</li><li>Mequitazine: risk of mequitazine adverse events (such as QT prolongation) may be increased because of an inhibition of its metabolism by fluoxetine.</li></ul><p>&nbsp;&nbsp;&nbsp; <em><u>Combinations requiring caution</u></em><em> </em></p><p><em>Phenytoin</em>: Changes in blood levels have been observed when combined with fluoxetine. In some cases manifestations of toxicity have occurred. Consideration should be given to using conservative titration schedules of the concomitant drug and to monitoring clinical status.</p><p><em>Serotoninergic drugs (lithium, tramadol, triptans, tryptophan,</em> <em>selegiline (MAOI-B), St. John&#39;s Wort (Hypericum perforatum))</em>: There have been reports of mild serotonin syndrome when SSRIs were given with drugs also having a serotoninergic effect. Therefore, the concomitant use of fluoxetine with these drugs should be undertaken with caution, with closer and more frequent clinical monitoring (see section 4.4).</p><p><em>QT interval prolongation</em>: Pharmacokinetic and pharmacodynamic studies between fluoxetine and other medicinal products that prolong the QT interval have not been performed. An additive effect of fluoxetine and these medicinal products cannot be excluded. Therefore, co-administration of fluoxetine with medicinal products that prolong the QT interval, such as Class IA and III antiarrhythmics, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine), anti-malaria treatment particularly halofantrine, certain antihistamines (astemizole, mizolastine), should be used with caution (see sections 4.4, 4.8 and 4.9).</p><p><em>Drugs affecting haemostasis (oral anticoagulants, whatever their mechanism, platelets antiaggregants including aspirin and NSAIDs)</em>: risk of increased bleeding. Clinical monitoring, and more frequent monitoring of INR with oral anticoagulants, should be made. A dose adjustment during the fluoxetine treatment and after its discontinuation may be suitable (see sections 4.4 and 4.8).</p><p><em>Cyproheptadine</em>: There are individual case reports of reduced antidepressant activity of fluoxetine when used in combination with cyproheptadine.</p><p><em>Drugs inducing hyponatremia</em>: Hyponatremia is an undesirable effect of fluoxetine. Use in combination with other agents associated with hyponatremia (e.g. diuretics, desmopressin, carbamazepine and oxcarbazepine) may lead to an increased risk (see section 4.8).</p><p><em>Drugs lowering the epileptogenic threshold</em>: Seizures are an undesirable effect of fluoxetine. Use in combination with other agents which may lower the seizure threshold (for example, TCAs, other SSRIs, phenothiazines, butyrophenones, mefloquine, chloroquine, bupropion, tramadol) may lead to an increased risk.</p><p><em>Other drugs metabolised by CYP2D6</em>: Fluoxetine is a strong inhibitor of CYP2D6 enzyme, therefore concomitant therapy with drugs also metabolised by this enzyme system may lead to drug interactions, notably those having a narrow therapeutic index (such as flecainide, propafenone and nebivolol) and those that are titrated, but also with atomoxetine, carbamazepine, tricyclic antidepressants and risperidone. They should be initiated at or adjusted to the low end of their dose range. This may also apply if fluoxetine has been taken in the previous 5 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Some epidemiological studies suggest an increased risk of cardiovascular defects associated with the use of fluoxetine during the first trimester. The mechanism is unknown. Overall the data suggest that the risk of having an infant with a cardiovascular defect following maternal fluoxetine exposure is in the region of 2/100 compared with an expected rate for such defects of approximately 1/100 in the general population.</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur.</p><p>Fluoxetine should not be used during pregnancy unless the clinical condition of the woman requires treatment with fluoxetine and justifies the potential risk to the foetus. Abrupt discontinuation of therapy should be avoided during pregnancy (see section 4.2 &ldquo;Posology and method of administration&rdquo;). If fluoxetine is used during pregnancy, caution should be exercised, especially during late pregnancy or just prior to the onset of labour, since some other effects have been reported in neonates: irritability, tremor, hypotonia, persistent crying, and difficulty in sucking or in sleeping. These symptoms may indicate either serotonergic effects or a withdrawal syndrome. The time to occur and the duration of these symptoms may be related to the long half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days).</p><p><u>Breast-feeding</u></p><p>Fluoxetine and its metabolite norfluoxetine, are known to be excreted in human breast milk. Adverse events have been reported in breastfeeding infants. If treatment with fluoxetine is considered necessary, discontinuation of breastfeeding should be considered; however, if breastfeeding is continued, the lowest effective dose of fluoxetine should be prescribed.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Animal data have shown that fluoxetine may affect sperm quality (see section 5.3).</p><p>Human case reports with some SSRI&#39;s have shown that an effect on sperm quality is reversible.</p><p>Impact on human fertility has not been observed so far.</p><p>* observational data indicate an increased risk (less than 2-fold) of postpartum haemorrhage following SSRI/ SNRI.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fluoxetine has no or negligible influence on the ability to drive and use machines. Although fluoxetine has been shown not to affect psychomotor performance in healthy volunteers, any psychoactive drug may impair judgement or skills. Patients should be advised to avoid driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile</p><p>The most commonly reported adverse reactions in patients treated with fluoxetine were headache, nausea, insomnia, fatigue and diarrhoea. Undesirable effects may decrease in intensity and frequency with continued treatment and do not generally lead to cessation of therapy.</p><p>&nbsp;</p><p>b. Tabulated list of adverse reactions</p><p>The table below gives the adverse reactions observed with fluoxetine treatment in adult and paediatric populations. Some of these adverse reactions are in common with other SSRIs.</p><p>The following frequencies have been calculated from clinical trials in adults (n = 9297) and from spontaneous reporting.</p><p>Frequency estimate: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Very Common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not Known</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Neutropenia</p><p>Leucopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic reaction</p><p>Serum sickness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Endocrine disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Inappropriate antidiuretic hormone secretion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Decreased appetite<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyponatraemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia<sup>2</sup></p></td><td style="vertical-align:top"><p>Anxiety</p><p>Nervousness</p><p>Restlessness</p><p>Tension</p><p>Libido decreased<sup>3</sup></p><p>Sleep disorder</p><p>Abnormal dreams<sup>4</sup></p></td><td style="vertical-align:top"><p>Depersonalisation</p><p>Elevated mood</p><p>Euphoric mood</p><p>Thinking abnormal</p><p>Orgasm abnormal<sup>5</sup></p><p>Bruxism</p><p>Suicidal thoughts and behaviour <sup>6</sup></p></td><td style="vertical-align:top"><p>Hypomania</p><p>Mania</p><p>Hallucinations</p><p>Agitation</p><p>Panic attacks</p><p>Confusion</p><p>Dysphemia</p><p>Aggression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Disturbance in attention</p><p>Dizziness</p><p>Dysgeusia</p><p>Lethargy</p><p>Somnolence<sup>7</sup></p><p>Tremor</p></td><td style="vertical-align:top"><p>Psychomotor hyperactivity</p><p>Dyskinesia</p><p>Ataxia</p><p>Balance disorder</p><p>Myoclonus</p><p>Memory impairment</p></td><td style="vertical-align:top"><p>Convulsion</p><p>Akathisia</p><p>Buccoglossal syndrome</p><p>Serotonin syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Eye disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Mydriasis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Cardiac disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Palpitations</p><p>Electrocardiogram QT prolonged (QTcF &ge;450 msec)<sup>8</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Ventricular arrhythmia including torsades de pointes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Vascular disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Flushing<sup>9</sup></p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Vasculitis</p><p>Vasodilatation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Yawning</p></td><td style="vertical-align:top"><p>Dyspnoea</p><p>Epistaxis</p></td><td style="vertical-align:top"><p>Pharyngitis</p><p>Pulmonary events (inflammatory processes of varying histopathology and/or fibrosis)<sup>10</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p><p>Nausea</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Dyspepsia</p><p>Dry mouth</p></td><td style="vertical-align:top"><p>Dysphagia</p><p>Gastrointestinal haemorrhage<sup>11</sup></p></td><td style="vertical-align:top"><p>Oesophageal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Hepato-biliary disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Idiosyncratic hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash<sup>12</sup></p><p>Urticaria</p><p>Pruritus</p><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Alopecia</p><p>Increased tendency to bruise</p><p>Cold sweat</p></td><td style="vertical-align:top"><p>Angioedema</p><p>Ecchymosis</p><p>Photosensitivity reaction</p><p>Purpura</p><p>Erythema multiforme</p><p>Stevens-Johnson syndrome</p><p>Toxic Epidermal Necrolysis (Lyell Syndrome)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Muscle twitching</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Frequent urination<sup>13</sup></p></td><td style="vertical-align:top"><p>Dysuria</p></td><td style="vertical-align:top"><p>Urinary retention</p><p>Micturition disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Gynaecological bleeding<sup>14</sup></p><p>Erectile dysfunction</p><p>Ejaculation disorder<sup>15</sup></p></td><td style="vertical-align:top"><p>Sexual dysfunction</p></td><td style="vertical-align:top"><p>Galactorrhoea</p><p>Hyperprolactinaemia</p><p>Priapism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Postpartum haemorrhage *</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>16</sup></p></td><td style="vertical-align:top"><p>Feeling jittery</p><p>Chills</p></td><td style="vertical-align:top"><p>Malaise</p><p>Feeling abnormal</p><p>Feeling cold</p><p>Feeling hot</p></td><td style="vertical-align:top"><p>Mucosal haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Investigations</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>Transaminases increased</p><p>Gamma-glutamyltransferase increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>1 </sup>Includes anorexia</p><p>2 Includes early morning awakening, initial insomnia, middle insomnia</p><p>3 Includes loss of libido</p><p>4 Includes nightmares</p><p>5 Includes anorgasmia</p><p>6 Includes completed suicide, depression suicidal, intentional self-injury, self-injurious ideation, suicidal behavior, suicidal ideation, suicide attempt, morbid thoughts, self injurious behaviour. These symptoms may be due to underlying disease</p><p>7 Includes hypersomnia, sedation</p><p>8 Based on ECG measurements from clinical trials</p><p>9 Includes hot flush</p><p>10 Includes atelectasis, interstitial lung disease, pneumonitis</p><p>11 Includes most frequently gingival bleeding, haematemesis, haematochezia, rectal haemorrhage, diarrhoea haemorrhagic, melaena, and gastric ulcerhaemorrhage</p><p>12 Includes erythema, exfoliative rash, heat rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash macular-papular, rash morbilliform, rash papular, rash pruritic, rash vesicular, umbilical erythema rash</p><p>13 Includes pollakiuria</p><p>&nbsp;</p><p>14 Includes cervix haemorrhage, uterine dysfunction, uterine bleeding, genital haemorrhage, menometrorhagia, menorrhagia, metrorrhagia, polymenorrhea, postmenopausal haemorrhage, uterine haemorrhage, vaginal haemorrhage</p><p>15 Includes ejaculation failure, ejaculation dysfunction, premature ejaculation, ejaculation delayed, retrograde ejaculation</p><p>16 Includes asthenia</p><p>* This event has been reported for the therapeutic class of SSRIs/ SNRIs.</p><p>c. Description of selected adverse reactions</p><p>Suicide/suicidal thoughts or clinical worsening: Cases of suicidal ideation and suicidal behaviour have been reported during fluoxetine therapy or early after treatment discontinuation (see section 4.4).</p><p>Bone fractures: Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to the risk is unknown.</p><p>Withdrawal symptoms seen on discontinuation of fluoxetine treatments: Discontinuation of fluoxetine commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), asthenia, agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported reactions. Generally these events are mild to moderate and are self-limiting, however, in some patients they may be severe and/or prolonged (see section 4.4). It is therefore advised that when fluoxetine treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see sections 4.2 and 4.4).</p><p>d. Paediatric population (see sections 4.4 and 5.1)</p><p>Adverse reactions that have been observed specifically or with a different frequency in this population are described below. Frequencies for these events are based on paediatric clinical trial exposures (n = 610).</p><p>In paediatric clinical trials, suicide-related behaviours (suicide attempt and suicidal thoughts), hostility (the events reported were: anger, irritability, aggression, agitation, activation syndrome), manic reactions, including mania and hypomania (no prior episodes reported in these patients) and epistaxis, were commonly reported and were more frequently observed among children and adolescents treated with antidepressants compared to those treated with placebo.</p><p>Isolated cases of growth retardation have been reported from clinical use (See also section 5.1).</p><p>In paediatric clinical trials, fluoxetine treatment was also associated with a decrease in alkaline phosphatase levels.</p><p>Isolated cases of adverse events potentially indicating delayed sexual maturation or sexual dysfunction have been reported from paediatric clinical use (See also section 5.3).</p><p>Saudi Arabia: To report any side effect(s): National Pharmacovigilance Center (NPC):&nbsp; Fax: +966-11-205-7662, SFDA Call center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Cases of overdose of fluoxetine alone usually have a mild course. Symptoms of overdose have included nausea, vomiting, seizures, cardiovascular dysfunction ranging from asymptomatic arrhythmias (including nodal rhythm and ventricular arrhythmias) or ECG changes indicative of QTc prolongation to cardiac arrest (including very rare cases of Torsade de Pointes), pulmonary dysfunction, and signs of altered CNS status ranging from excitation to coma. Fatality attributed to overdose of fluoxetine alone has been extremely rare.</p><p>&nbsp;</p><p><u>Management</u></p><p>Cardiac and vital signs monitoring are recommended, along with general symptomatic and supportive measures. No specific antidote is known.</p><p>Forced diuresis, dialysis, haemoperfusion, and exchange transfusion are unlikely to be of benefit. Activated charcoal, which may be used with sorbitol, may be as or more effective than emesis or lavage. In managing overdosage, consider the possibility of multiple drug involvement. An extended time for close medical observation may be needed in patients who have taken excessive quantities of a tricyclic antidepressant if they are also taking, or have recently taken, fluoxetine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Selective serotonin reuptake inhibitors.</p><p>&nbsp;ATC code: N06A B03.</p><p><u>Mechanism of action</u></p><p>Fluoxetine is a selective inhibitor of serotonin reuptake, and this probably accounts for the mechanism of action. Fluoxetine has practically no affinity to other receptors such as &alpha;<sub>1</sub>-, &alpha;<sub>2</sub>-, and &beta;-adrenergic; serotonergic; dopaminergic; histaminergic1; muscarinic; and GABA receptors.</p><p><u>Clinical efficacy and safety</u></p><p>Major depressive episodes: Clinical trials in patients with major depressive episodes have been conducted versus placebo and active controls. Fluoxetine has been shown to be significantly more effective than placebo, as measured by the Hamilton Depression Rating Scale (HAM-D). In these studies, Fluoxetine produced a significantly higher rate of response (defined by a 50% decrease in the HAM-D score) and remission compared to placebo.</p><p>Dose response: In the fixed-dose studies of patients with major depression there is a flat dose response curve, providing no suggestion of advantage in terms of efficacy for using higher than the recommended doses. However, it is clinical experience that uptitrating might be beneficial for some patients.</p><p>Obsessive-compulsive disorder: In short-term trials (under 24 weeks), fluoxetine was shown to be significantly more effective than placebo. There was a therapeutic effect at 20mg/day, but higher doses (40 or 60mg/day) showed a higher response rate. In long-term studies (three short-term studies extension phase and a relapse prevention study), efficacy has not been shown.</p><p>Bulimia nervosa: In short-term trials (under 16 weeks), in out-patients fulfilling DSM-III-R-criteria for bulimia nervosa, fluoxetine 60mg/day was shown to be significantly more effective than placebo for the reduction of bingeing, vomiting and purging activities. However, for long-term efficacy no conclusion can be drawn.</p><p>Pre-Menstrual Dysphoric Disorder: Two placebo-controlled studies were conducted in patients meeting pre-menstrual dysphoric disorder (PMDD) diagnostic criteria according to DSM-IV. Patients were included if they had symptoms of sufficient severity to impair social and occupational function and relationships with others. Patients using oral contraceptives were excluded. In the first study of continuous 20mg daily dosing for 6 cycles, improvement was observed in the primary efficacy parameter (irritability, anxiety and dysphoria). In the second study, with intermittent luteal phase dosing (20mg daily for 14 days) for 3 cycles, improvement was observed in the primary efficacy parameter (Daily Record of Severity of Problems score). However, definitive conclusions on efficacy and duration of treatment cannot be drawn from these studies.</p><p><u>Paediatric population</u></p><p>Major depressive episodes: Clinical trials in children and adolescents aged 8 years and above have been conducted versus placebo. Fluoxetine, at a dose of 20mg, has been shown to be significantly more effective than placebo in two short-term pivotal studies, as measured by the reduction of Childhood Depression Rating Scale-Revised (CDRS-R) total scores and Clinical Global Impression of Improvement (CGI-I) scores. In both studies, patients met criteria for moderate to severe MDD (DSM-III or DSM-IV) at three different evaluations by practising child psychiatrists. Efficacy in the fluoxetine trials may depend on the inclusion of a selective patient population (one that has not spontaneously recovered within a period of 3-5 weeks and whose depression persisted in the face of considerable attention). There is only limited data on safety and efficacy beyond 9 weeks. In general, efficacy of fluoxetine was modest. Response rates (the primary endpoint, defined as a 30% decrease in the CDRS-R score) demonstrated a statistically significant difference in one of the two pivotal studies (58% for fluoxetine versus 32% for placebo, P = 0.013; and 65% for fluoxetine versus 54% for placebo, P = 0.093). In these two studies, the mean absolute changes in CDRS-R from baseline to endpoint were 20 for fluoxetine versus 11 for placebo, P = 0.002; and 22 for fluoxetine versus 15 for placebo, P &lt;0.001.</p><p>Effects on growth, see sections 4.4 and 4.8: After 19 weeks of treatment, paediatric subjects treated with fluoxetine in a clinical trial gained an average of 1.1 cm less in height (p=0.004) and 1.1 kg less in weight (p=0.008) than subjects treated with placebo.</p><p>In a retrospective matched control observational study with a mean of 1.8 years of exposure to fluoxetine, paediatric subjects treated with fluoxetine had no difference in growth adjusted for expected growth in height from their matched, untreated controls (0.0 cm, p=0.9673). &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption: Fluoxetine is well absorbed from the gastro-intestinal tract after oral administration. The bioavailability is not affected by food intake.</p><p>Distribution: Fluoxetine is extensively bound to plasma proteins (about 95%) and it is widely distributed (volume of distribution: 20-40 L/kg). Steady-state plasma concentrations are achieved after dosing for several weeks. Steady-state concentrations after prolonged dosing are similar to concentrations seen at 4 to 5 weeks.</p><p>Biotransformation: Fluoxetine has a non-linear pharmacokinetic profile with first-pass liver effect. Maximum plasma concentration is generally achieved 6 to 8 hours after administration. Fluoxetine is extensively metabolised by the polymorphic enzyme CYP2D6. Fluoxetine is primarily metabolised by the liver to the active metabolite norfluoxetine (desmethylfluoxetine), by desmethylation.</p><p>Elimination: The elimination half-life of fluoxetine is 4 to 6 days and for norfluoxetine 4 to 16 days. These long half-lives are responsible for persistence of the drug for 5-6 weeks after discontinuation. Excretion is mainly (about 60%) via the kidney. Fluoxetine is secreted into breast milk.</p><p><u>Special populations</u></p><p>Elderly: Kinetic parameters are not altered in healthy elderly when compared to younger subjects.</p><p>Paediatric population: The mean fluoxetine concentration in children is approximately 2-fold higher than that observed in adolescents and the mean norfluoxetine concentration 1.5-fold higher. Steady-state plasma concentrations are dependent on body weight and are higher in lower-weight children (see section 4.2). As in adults, fluoxetine and norfluoxetine accumulated extensively following multiple oral dosing; steady-state concentrations were achieved within 3 to 4 weeks of daily dosing.</p><p>Hepatic insufficiency: In case of hepatic insufficiency (alcoholic cirrhosis), fluoxetine and norfluoxetine half-lives are increased to 7 and 12 days, respectively. A lower or less frequent dose should be considered.</p><p>Renal insufficiency: After single-dose administration of fluoxetine in patients with mild, moderate, or complete (anuria) renal insufficiency, kinetic parameters have not been altered when compared to healthy volunteers. However, after repeated administration, an increase in steady-state plateau of plasma concentrations may be observed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence of carcinogenicity or mutagenicity from in vitro or animal studies.</p><p><u>Adult animal studies</u></p><p>In a 2-generation rat reproduction study, fluoxetine did not produce adverse effects on the mating or fertility of rats, was not teratogenic, and did not affect growth, development, or reproductive parameters of the offspring.</p><p>The concentrations in the diet provided doses approximately equivalent to 1.5, 3.9, and 9.7 mg fluoxetine/kg body weight.</p><p>Male mice treated daily for 3 months with fluoxetine in the diet at a dose approximately equivalent to 31 mg/kg showed a decrease in testis weight and hypospermatogenesis. However, this dose level exceeded the maximum-tolerated dose (MTD) as significant signs of toxicity were seen.</p><p><u>Juvenile animal studies</u></p><p>In a juvenile toxicology study in CD rats, administration of 30 mg/kg/day of fluoxetine hydrochloride on postnatal days 21 to 90 resulted in irreversible testicular degeneration and necrosis, epididymal epithelial vacuolation, immaturity and inactivity of the female reproductive tract and decreased fertility. Delays in sexual maturation occurred in males (10 and 30 mg/kg/day) and females (30 mg/kg/day). The significance of these findings in humans is unknown. Rats administered 30 mg/kg also had decreased femur lengths compared with controls and skeletal muscle degeneration, necrosis and regeneration. At 10 mg/kg/day, plasma levels achieved in animals were approximately 0.8 to 8.8 fold (fluoxetine) and 3.6 to 23.2 fold (norfluoxetine) those usually observed in paediatric patients. At 3 mg/kg/day, plasma levels achieved in animals were approximately 0.04 to 0.5 fold (fluoxetine) and 0.3 to 2.1 fold (norfluoxetine) those usually achieved in paediatric patients.</p><p>A study in juvenile mice has indicated that inhibition of the serotonin transporter prevents the accrual of bone formation. This finding would appear to be supported by clinical findings. The reversibility of this effect has not been established.</p><p>Another study in juvenile mice (treated on postnatal days 4 to 21) has demonstrated that inhibition of the serotonin transporter had long-lasting effects on the behaviour of the mice. There is no information on whether the effect was reversible. The clinical relevance of this finding has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:359px"><tbody><tr><td style="vertical-align:top"><p>&sect;&nbsp; Maize starch</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Lactose</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Povidon K29-32</p></td></tr><tr><td style="vertical-align:top"><p>&sect;&nbsp; Colloidal Anhydrous Silica</p><p>&sect;&nbsp; Magnesium Stearate</p><p>&sect;&nbsp; Hydroxypropyl Methylcelluose Type 2910</p><p>&sect;&nbsp; Polyethylene Glycol 400</p><p>&sect;&nbsp; Titanium Dioxide</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C, protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect;&nbsp; <strong>OXETINE 20 </strong>Tablets are packed in boxes of 10 Tablets blistered in PVC/aluminium foil blister</p><p>&sect;&nbsp; <strong>OXETINE 20 </strong>Tablets are packed in boxes of 20 Tablets blistered in PVC/aluminium foil blister</p><p>&sect;&nbsp; <strong>OXETINE 20 </strong>Tablets are packed in boxes of 30 Tablets blistered in PVC/aluminium foil blister.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2020.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>